Inhibition of glial scarring in the injured rat brain by a recombinant human monoclonal antibody to transforming growth factor‐β2
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
The transforming growth factor‐βs (TGF‐βs) are potent fibrogenic factors implicated in numerous central nervous system (CNS) pathologies in which fibrosis and neural dysfunction are causally associated. In this study, we aim to limit the fibrogenic process in a model of CNS scarring using a recombinant human monoclonal antibody, derived from phage display libraries and specific to the active form of the TGF‐β2 isoform. The implicit inference of the work was that, as such antibodies are potential pharmacological agents for the treatment of human CNS fibrotic diseases, validation of efficacy in a mammalian animal model is a first step towards this end. Treatment of cerebral wounds with the anti‐TGF‐β2 antibody led to a marked attenuation of all aspects of CNS scarring, including matrix deposition, formation of an accessory glial‐limiting membrane, inflammation and angiogenesis. For example, in the wound, levels of: (i) the connective tissue components fibronectin, laminin and chondroitin sulphate proteoglycan; and (ii) wound‐responsive cells including astrocytes and macrophages/microglia, were markedly reduced. Our findings suggest that such synthetic anti‐fibrotic TGF‐β antibodies are potentially applicable to a number of human CNS fibrotic diseases to arrest the deposition of excessive extracellular matrix components, and maintain and/or restore functional integrity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ignotz, R. A., & Massagué, J. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)35666-1 · Cited by 2,492
The DHC1b (DHC2) Isoform of Cytoplasmic Dynein Is Required for Flagellar Assembly
Pazour, G. J., Dickert, B. L., & Witman, G. B. (1999) · The Journal of Cell Biology · doi:10.1083/jcb.144.3.473 · Cited by 471
Amyloidogenic role of cytokine TGF-β1 in transgenic mice and in Alzheimer's disease
Wyss-Coray, T., Masliah, E., Mallory, M., McConlogue, L., Johnson-Wood, K., Lin, C., & Mucke, L. (1997) · Nature · doi:10.1038/39321 · Cited by 417 · cited 2×
“, 1996) and sub-arachnoid haemorrhage (Kitazawa & Tada, 1994); TGF-bs may also promote plaque development in Alzheimer's disease and Downs syndrome (Wyss-Coray et al., 1997).”
BackgroundRegulation of Cell Adhesion Receptors by Transforming Growth Factor-β
Ignotz, R. A., Heino, J., & Massagué, J. (1989) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)31270-x · Cited by 269
Cited by
Neural Tissue Engineering: Strategies for Repair and Regeneration
Schmidt, C. E., & Leach, J. B. (2003) · Annual Review of Biomedical Engineering · doi:10.1146/annurev.bioeng.5.011303.120731 · Cited by 1,237
Regenerating the damaged central nervous system
Horner, P. J., & Gage, F. H. (2000) · Nature · doi:10.1038/35039559 · Cited by 831
Chapter 22 Chondroitin sulphate proteoglycans in the CNS injury response
Morgenstern, D. A., Asher, R. A., & Fawcett, J. W. (2002) · Progress in Brain Research · doi:10.1016/s0079-6123(02)37024-9 · Cited by 419
Antifibrotics and Wound Healing in Glaucoma Surgery
Lama, P. J., & Fechtner, R. D. (2003) · Survey of Ophthalmology · doi:10.1016/s0039-6257(03)00038-9 · Cited by 389
Tang, X., Davies, J. E., & Davies, S. J. A. (2003) · Journal of Neuroscience Research · doi:10.1002/jnr.10523 · Cited by 386
Metadata
- Authors
- Logan, A., Green, J., Hunter, A., Jackson, R., & Berry, M.
- Venue
- European Journal of Neuroscience
- Publisher
- Wiley
- Published
- 1999-07
- Volume
- 11
- Issue
- 7
- Pages
- 2367-2374
- ISSN
- 0953-816X (ISSN-L)
- 1460-9568
- OpenAlex
- W2056461470
- Cited by
- 119
- References
- 4
- FWCI
- 7.78
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inhibition of glial scarring in the injured rat brain by a recombinant human monoclonal antibody to transforming growth factor‐β2. https://app.cochat.ai/papers/10.1046/j.1460-9568.1999.00654.x
- The paper
- Logan, A., Green, J., Hunter, A., Jackson, R., & Berry, M. (1999). Inhibition of glial scarring in the injured rat brain by a recombinant human monoclonal antibody to transforming growth factor‐β2. European Journal of Neuroscience. https://doi.org/10.1046/j.1460-9568.1999.00654.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.